Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Tardy, Magdolna ^a   Huhn, Maximilian ^a   Engel, Rolf R ^b   Leucht, Stefan ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; THIORIDAZINE;

AKATHISIA; AKINESIA; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; DYSKINESIA; HUMAN; LEUKOPENIA; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TOXICITY; TREATMENT RESPONSE; VASOMOTOR DISORDER; ADULT; META ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; HUMANS; PERPHENAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84921941835     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009369.pub2     Document Type: Review

References (68)

1. Adelson D, Epstein LJ. A study of phenothiazines with males and female chronically ill schizophrenic patients. Journal of Nervous and Mental Diseases 1962;134(1):543-54.
2. Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA. The comparative effectiveness of eight phenothiazines. Psychopharmacologia 1965;7:89-106.
3. Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AM. The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. Journal of Nervous and Mental Disease 1961;133:1-18.
4. Shalev A, Hermesh H, Rothberg J, Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica 1993;87(2):86-91.
5. Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R. Current status of pharmacotherapy in schizophrenia. Folia Psychiatrica et Neurologica Japonica 1966;20(1):1-8.
6. Anon. A new comparison of antipsychotic drugs. Harvard Mental Health Letter 2006;22(7):7.
7. Bennett JL, Kooi KA. Five phenothiazine derivatives. Evaluation and toxicity studies. Archives of General Psychiatry 1961;4:413-8.
8. Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with phenothiazine derivatives. American Journal of Psychiatry 1960;August 1960:97-105.
9. Hollister LE, Overall JE, Kimbell IJ, Pokorny A. Specific indications for different classes of phenothiazines. Archives of General Psychiatry 1974;30(1):94-9.
10. Lapolla A. A double-blind evaluation of chlorpromazine versus a combination of perphenazine and amitriptyline. International Journal of Neuropsychiatry 1967;3(5):403-5.
11. Loza B, Kucharska-Pietura K, Debowska G. Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores. European Neuropsychopharmacology 2001;11(3):285.
12. Gerlach J. Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale 1988;14:227-32.
13. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology 1986;90(4):423-9.
14. Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J. The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden [Neuroleptikas virkning pa tardive dyskinesier. En videokontrolleret, randomiseret undersogelse med klorprotixen, perfenazin, haloperidol og haloperidol + biperiden]. Ugeskrift for Laeger 1987;149(25):1682-5.
15. Schulsinger F, Jensen R. Trilafon (perphenazine) and largactil (chlorpromazine) in chronic schizophrenia. A comparison [Trilafon (perfenazin) og Largactil (klorpromazin) hos kronisk sindssyge]. Ugeskrift For Laeger 1958;120(12):366-9.
16. Smith JA, Christian D, Mansfield E, Figaredo A. A graphic comparison of five phenothiazines. American Journal of Psychiatry 1959;116:392-9.
17. Svestka J, Nahunek K. A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses. Activitas Nervosa Superior 1972;14(2):93-4. [MEDLINE: 4557145].
18. Svestka J, Nahunek K, Rodova A, Ceskova E. A controlled comparison of oxypertine and perphenazine in schizophrenic psychoses. Activitas Nervosa Superior 1974;16(3):165-6.
19. Vinar O. Differences in therapeutic effects of phenothiazine drugs. Agressologie 1968;9(2):315-7.
20. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
21. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic drug equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 2010;67:255-62.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III). Washington DC: American Psychiatric Association, 1980.
23. Berger M. Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. München: Urban & Fischer, 2003.
24. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
25. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
26. Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy 2000;5:12-6.
27. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
28. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry 1975;132(12):1237-45.
29. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Williams and Wilkins, 1989.
30. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town, 2000.
31. Der-Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
32. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
33. Dold M, Li C, Tardy M, Leucht S. Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009831].
34. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
35. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
36. Falkai P, Wobrock T, Lieberman J. World Federation of Societies of Biological Psychiatry (WFSBP) - guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry 2005;6:132-91.
37. Fenton M, Rathbone J, Reilly J, Sultana A. Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001944.pub2; PUBMED: 17636691].
38. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
39. Gaebel W, Falkai P, Weinmann S. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006.
40. GRADE Working Group. GRADE Profiler. 3.2. GRADE Working Group, 2004.
41. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
42. Haase HJ. Dosierung der Neuroleptika. Ein Leitfaden für Klinik und Praxis unter besonderer Berücksichtigung psychotisch Kranker. Erlangen: Perimed Fachbuch-Verlagsgesellschaft, 1983.
43. Hartung B, Wada M, Laux G, Leucht S. Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD009369].
44. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
45. Jones PB, Barnes TRE, Davies L. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia - cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-86.
46. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
47. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, MD: Williams and Wilkins, 1969.
48. Lehman AF, Lieberman JA, Dixon LB. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161:1-56.
49. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59:1001-5.
50. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
51. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
52. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41. [PUBMED: 19058842].
53. Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
54. Lohse MJ, Lorenzen A, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Pfaffrath D editor(s). Arzneimittelverordnungsreport. Berlin: Springer, 2005:820-64.
55. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
56. Marwaha S, Johnson S. Schizophrenia and employment - a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
57. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al.CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
58. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-12.
59. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
60. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
61. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188(4194):1217-9.
62. Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD009227;: CD009227].
63. Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD009230;: CD009230].
64. Tardy M, Leucht S, Potapov A, Kissling W, Engel R, Huhn M, et al.Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009268;: CD009268].
65. Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009396;: CD009396].
66. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al.Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology 2004;57(11):1124-30.
67. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
68. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.